Skip to content
effecthub

Aidoc vs Viz.ai

Two fact sheets from our own research, side by side — pricing, platforms, API access and status re-checked by us rather than quoted from the vendors.

The short answer

Best fit
Aidoc: Hospital systems and radiology groups wanting multi-pathology triage from one platform · Viz.ai: Hospital systems and stroke networks that want imaging-triggered alerts to reach neurointerventional teams faster
Platforms
Aidoc: Web · Viz.ai: Web, iOS, Android
Trust score
About even — Aidoc 90, Viz.ai 88
Status
Both up at our last check (Sep 6, 2026)

From our own records as of each tool's last check. Anything we have not confirmed is left out rather than guessed. How we verify

Side by side

FactAidocViz.ai
CategoryHealthcare & MedicalHealthcare & Medical
Pricing modelContactContact
Trust score90 / 10088 / 100
PlatformsWebWeb, iOS, Android
CompanyAidoc Medical Ltd.Viz.ai, Inc.
Launched20162016
Last verifiedSep 6, 2026Sep 6, 2026

What our research says

Aidoc

For a hospital that wants one vendor covering the common emergency findings rather than a point solution per pathology, Aidoc is the broadest cleared portfolio on a single platform, and the clinical evidence base (230+ studies by its own count) is unusually deep. It is enterprise medical software: there is no price, no trial and nothing for an individual radiologist or developer to pick up.

Pros

  • 17 FDA clearances and CE-marked algorithms across neuro, chest, vascular, bone, breast and abdomen
  • One platform orchestrates Aidoc's own and third-party algorithms with performance monitoring
  • Care-coordination layer integrates with PACS, EHR, RIS and scheduling
  • Named deployments at major European academic centres and 1,600+ hospitals claimed
  • Foundation-model work (CARE) with an FDA breakthrough designation for report drafting

Cons

  • No published pricing or trial; enterprise sales only
  • No public API or developer documentation found
  • Clearances are per condition, so coverage depends on which modules a site licenses
  • FDA and CE lists differ, which complicates multi-country rollouts

Viz.ai

Viz.ai is clinical infrastructure rather than a tool anyone signs up for: it sits on a hospital's imaging feed, and its value is the minutes it shaves between a scan and a specialist seeing it. The stroke work is the proven core, with the longest track record and the most clearances; the newer cardio, oncology and pilot suites are expansions a buyer should evaluate module by module. Nothing is priced publicly, procurement is an enterprise sale with IT and compliance review, and the algorithms are only as useful as the care pathway the hospital builds around the alerts.

Pros

  • More than 50 FDA-cleared algorithms across neuro, vascular, cardio, pulmonary, trauma and oncology
  • Alerts and images go to the specialist's phone, so the care pathway starts before the radiology read
  • One platform (Viz.ai One) rather than a separate vendor per finding
  • Founded in 2016 with a named clinical founder, so the stroke pathway has years of deployment behind it

Cons

  • No public pricing, trial or self-serve path; every engagement is a sales process
  • Value depends on hospital workflow changes around the alerts, not on the software alone
  • Newer suites and pilot programmes have less published evidence than the stroke module
  • Headquarters and funding details are not stated on the site

Which one fits

Choose Aidoc if you need

  • Hospital systems and radiology groups wanting multi-pathology triage from one platform
  • Stroke, PE and trauma programmes that need findings routed to care teams, not just flagged
  • Imaging IT teams that want third-party algorithms managed through one orchestrator

Choose Viz.ai if you need

  • Hospital systems and stroke networks that want imaging-triggered alerts to reach neurointerventional teams faster
  • Health systems consolidating several triage algorithms (stroke, PE, aortic, cardiac) under one coordination platform
  • Pharma and device companies looking for a deployed channel to identify patients for specific therapies

Browse all Healthcare & Medical →